Physician

Ven Chung Chiang, MD

According to 2025 Medicare claims, Ven Chiang, MD (NPI: 1447367453) practices nephrology in the Valdosta, GA market, with the plurality of this provider's patient population coming from Lowndes, GA. This provider's primary affiliated billing organization is VALDOSTA KIDNEY CLINIC, LLC (NPI: 1215109087; TIN: 20-1201744) and primary practice location at 31601-6347. Chiang is affiliated with the Caravan Health ACO 50 LLC (ACO ID: A5160), participating under the MSSP model.

Chiang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 310 traditional Medicare patients, billed 1,682 HCPCS/CPT codes, and received $163,304 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 1,965 prescription claims across 226 beneficiaries totaling $538,217 in drug costs, led by Kerendia (Finerenone). DME data shows 73 claims. Open Payments data shows 36 records totaling $820. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $504,874 to $163,304. Similarly, Part D prescription costs have declined steadily, from $791,079 to $538,217. In contrast, DME billing represents a smaller volume and declined steadily, from $967 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,082	5,219	$504,874
2016	1,064	4,864	$491,021
2017	951	4,961	$495,565
2018	946	5,645	$552,226
2019	877	4,819	$500,349
2020	698	3,879	$447,661
2021	604	3,262	$424,249
2022	496	2,803	$343,336
2023	346	2,297	$232,116
2024	310	1,682	$163,304

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	503	7,004	$791,079
2016	508	6,411	$876,022
2017	466	5,801	$1,122,269
2018	422	4,720	$612,658
2019	363	3,726	$490,226
2020	312	3,083	$574,742
2021	288	2,532	$432,378
2022	275	2,335	$584,720
2023	248	2,064	$562,815
2024	226	1,965	$538,217

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	11	$262
2016	N/R	12	$199
2017	N/R	108	$5,635
2018	N/R	238	$14,061
2019	N/R	245	$29,189
2020	N/R	181	$30,847
2021	N/R	208	$6,219
2022	N/R	205	$3,931
2023	N/R	220	$4,072
2024	N/R	73	$878

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	39	159	$270
90961	Dialysis services, 2-3 physician visits per month (20 years or older)	44	129	$225
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	80	117	$100
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	110	205	$64
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	129	560	$60

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Kerendia	Finerenone	182	6,950	$152,727
Velphoro	Sucroferric Oxyhydroxide	59	1,752	$102,558
Farxiga	Dapagliflozin Propanediol	136	5,440	$100,400
Veltassa	Patiromer Calcium Sorbitex	29	1,034	$34,867
Jardiance	Empagliflozin	13	1,050	$19,484

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	34	$426
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	26	$305
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	13	$147

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	36	$820	Otsuka America Pharmaceutical, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ven Chung Chiang, MD?

Tedicare shows public-source Medicare data for Ven Chung Chiang, MD (NPI 1447367453), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ven Chung Chiang, MD have ACO affiliation data?

Ven Chung Chiang, MD is shown with ACO affiliation data for Caravan Health ACO 50 LLC (MSSP, ACO ID A5160).

What billing organization is linked to Ven Chung Chiang, MD?

Ven Chung Chiang, MD is linked to VALDOSTA KIDNEY CLINIC, LLC (billing NPI 1215109087) in the available physician profile data.

Does Ven Chung Chiang, MD have Open Payments data?

Ven Chung Chiang, MD has 36 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.